mRNA Therapeutics & Genome Editingkeyboard_arrow_right
Search & Filter keyboard_arrow_right
keyboard_arrow_left Hide
mRNA Therapeutics & Genome Editing
keyboard_arrow_leftSearch & Filter
search
Free / Premium
Topics
mRNA Therapeutics & Genome Editing
search
Free / Premium
Topics
mRNA THERAPEUTICS & GENOME EDITING: Hear updates on discovery strategies, clinical progress and CMC approaches for mRNA therapeutics and vaccines from industry-leading companies, and learn about state-of-the-art technologies for genome editing applications and hear about progress in genome editing delivery
Showing 3 of 3 Streams
On-Demand Presentations
Webinars
Whitepapers & Case Studies
On Demand - For MembersFree
Designing Formulations to Enable a Broad Portfolio of mRNA Medicines
- Luis Brito, PhD - Director, Formulation Design, Moderna Therapeutics
On Demand - Premium Only
Manufacturing and CMC Approaches to mRNA Therapeutics
- Christoph Kroener - Head of Lead Structure and DNA Template Development for Individualized RNA Products, BioNTech AG
On Demand - Premium Only
Rapid Deployment of a Messenger RNA Vaccine for Pandemic Response
- Don Parsons, PhD - VP, Early Technical Development and LNP Process Development, Moderna Therapeutics
On Demand - Premium Only
Complexities of Characterizing Guide RNAs for CRISPR Applications
- Steven Wolk, Ph.D. - Senior Director of Analytical Chemistry, Editas Medicine
On Demand - Premium Only
Insights into CRISPR Double-Stranded Break Repair through CRISPAltRations: A Stringently Validated Analysis Pipeline for Genome Editing Outcomes
- Matthew McNeill. PhD - Senior Bioinformatics Staff Scientist, Integrated DNA Technologies
On Demand - Premium Only
Engineered Amphiphilic Peptides Enable Delivery of CRISPR-associated Nucleases to Airway Epithelial Cells
- David Guay, PhD - Research Director, Feldan Therapeutics
On Demand - Premium Only
Delivery of Gene Therapy and Gene Editing with Polymer Nanoparticle
- Kunwoo Lee, PhD - Chief Executive Officer, GenEdit
On Demand - Premium Only
Delivering RNA by Testing Thousands of Nanoparticles in vivo
- James Dahlman, PhD - Assistant Professor, Biomedical Engineering, Georgia Institute of Technology and Emory Medical School
On Demand - Premium Only
Improving Delivery by Chemical Modification of sgRNAs/Making Conjugates of sgRNA
- Nadia Amrani, PhD - Assistant Professor, RNA Therapeutics Institute, University of Massachusetts Medical School
On Demand - Premium Only
Optimization of Lipid Nanoparticles for Delivery of mRNA
- Luis Brito, PhD - Director, Formulation Design, Moderna Therapeutics
On Demand - Premium Only
Developing 3D Cell Culture Models of the Respiratory Tract to Assess Antiviral Activity of siRNA against SARSCoV2
- Olivia Merkel - Professor, Department of Pharmacy, Ludwig-Maximilians-Universität München
On Demand - Premium Only
Regulatory Quality and CMC Perspectives on mRNA Vaccines and Peptide Vaccine Adjuvants: Special Focus on COVID-19 mRNA Vaccines
- Ralf Wagner - Head Section Viral Vaccines, Paul-Ehrlich-Institut
On Demand - Premium Only
Usage of an mRNA Platform Technology for “Light Speed” Development of a Vaccine against SARS-CoV-2”
- Andreas Kuhn, PhD - Vice President, RNA Biochemistry & Manufacturing, BioNTech RNA Pharmaceuticals GmbH
On Demand - For MembersFree
CMC Considerations for mRNA Based Therapeutics
- Ashleigh Wake - C&P Business Development Director, Intertek Pharmaceutical Services
On Demand - For MembersFree
CASE STUDY: CMC Considerations for mRNA Based Therapeutics - Analytical Approaches to Characterize Capital Quality Attributes
Jo-Anne Riley, Senior Scientist, Intertek Pharmaceutical Services discusses analytical development approaches to overcome challenges in the characterisation of mRNA therapies.
mRNA is a growing field of medicinal research with the potential to not just treat but cure disease. The complex approach to manufacturing mRNA, as well as the intracellular delivery method, can bring impurity risks that impact the efficacy and safety of the drug.
This article discusses analytical approaches to characterise mRNA in early-stage development to support effective therapeutic programs.
Filter
Free / Premium
Topics